The Plymouth pharma startup Esperion Therapeutics Inc. (Nasdaq: ESPR), Wednesday announced the first patient in a Phase 2b clinical study had received the first dose of ETC-1002, its lead anti-cholesterol drug.
Esperion Therapeutics Inc. (Nasdaq: ESPR), an early-stage pharmaceutical company developing a new class of cholesterol-fighting drugs, Monday provided financial figures and a corporate update.
The Ann Arbor biotech firm Esperion Therapeutics Inc. announced that it has completed a $33 million preferred stock financing led by new investor Longitude Capital.
Cerenis Therapeutics, the pharma company developing new high-density lipoprortein therapies for cardiovascular and metabolic diseases, Tuesday appointed Richard C. Pasternak to the board of directors and John F. Paolini, M.D., as Chief Medical Officer.
The Plymouth pharmaceutical developer Esperion Therapeutics Thursday announced that it has initiated a Phase 2 clinical study for ETC-1002, the company’s lead product candidate. ETC-1002 is a novel small molecule compound that has demonstrated preclinical […]